FDA Approves Biosimilar to Humira – IBD in the News

Pharma, life science and medical news Aug 1st weekПодробнее

Understanding Biosimilars - For IBD PatientsПодробнее

FDA approves Rinvoq as first pill to treat moderate-to-severe Crohn's DiseaseПодробнее

FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.Подробнее

Navigating Insurance as a Crohn's or Colitis Patient: What is a Biosimilar?Подробнее

FDA Approves Entyvio for IBD Patients -- IBD in the NewsПодробнее

Biosimilars and Inflammatory Bowel DiseaseПодробнее

The Promise of BiosimilarsПодробнее

FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.Подробнее

Understanding Biosimilars - What IBD Patients Should KnowПодробнее

Why IBD Patients Should Know About BiosimilarsПодробнее

The Current Landscape of Biosimilars in IBDПодробнее

Biosimilars for IBD: To Start, Switch, or Stay Away?Подробнее

Understanding biosimilars: what IBD patients & caregivers need to knowПодробнее

Highlights of ACG's Annual Scientific Meeting, 2015 - IBD in the NewsПодробнее

Biosimilars in the US and BeyondПодробнее

Biosimilars in IBD: Where Do We Stand Today?Подробнее

DEBATE: Biosimilar Therapies - Caution, more studies are neededПодробнее

FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.Подробнее

Are you scared about biosimilars? #IBD #shorts #biosimilar #biologic #humiraПодробнее

Biosimilars for IBD: Start, Switch, or Stay Away?Подробнее